Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BVX-1021,BVX-0320
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Biovaxys
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.
Brand Name : BVX-1021
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 06, 2022
Lead Product(s) : BVX-1021,BVX-0320
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Biovaxys
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?